Guangzhou Innogen Pharmaceutical Group Co Ltd (hkse:02591) Share Price

Company Profile

Business description
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize an innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize innovative therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates targeting diabetes and other metabolic diseases.
Contact
No. 2 Tengfei Second Street
Room 409, Building H Self-numbered Creative Building
China-Singapore Guangzhou Knowledge City
Huangpu District, Guangdong Province
Guangzhou
CHN
https://www.innogenpharm.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
96

Recommended

This share is trading at the lowest price to fair value of the 14 companies on the list.

Angus Hewitt, CFA | 05 January 2026

Despite a surging share price a weakening competitive position causes a reassessment of our view.

Shane Ponraj, CFA | 05 January 2026

We believe these companies’ strong ESG management practices give them a long-term advantage.

Margaret Giles | 04 January 2026

Index	Last price	Change	% Change
All Ordinaries	9,030.30	45.40	-0.50%
CAC 40	8,211.50	16.29	0.20%
DAX 40	24,868.69	329.35	1.34%
Dow JONES (US)	48,977.18	594.79	1.23%
FTSE 100	10,004.57	53.43	0.54%
HKSE	26,513.76	166.52	0.63%
NASDAQ	23,395.82	160.19	0.69%
Nikkei 225	52,236.17	403.37	0.78%
NZX 50 Index	13,648.86	61.63	0.45%
S&P 500	6,902.05	43.58	0.64%
S&P/ASX 200	8,718.30	53.00	-0.60%
SSE Composite Index	4,032.31	8.89	0.22%